BioStem Technologies, Inc. (BSEM)
OTCMKTS · Delayed Price · Currency is USD
7.20
-0.49 (-6.37%)
Jan 29, 2026, 3:58 PM EST
BioStem Technologies Revenue
BioStem Technologies had revenue of $10.47M in the quarter ending September 30, 2025, a decrease of -43.12%. This brings the company's revenue in the last twelve months to $292.21M, up 399.02% year-over-year. In the year 2024, BioStem Technologies had annual revenue of $301.83M with 1,708.93% growth.
Revenue (ttm)
292.21M
Revenue Growth
+399.02%
P/S Ratio
0.44
Revenue / Employee
8.85M
Employees
33
Market Cap
129.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 301.83M | 285.14M | 1,708.93% |
| Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
| Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
| Dec 31, 2021 | 4.34M | 4.03M | 1,284.88% |
| Dec 31, 2017 | 313.45K | -293.78K | -48.38% |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Arch Biopartners | 198.11K |
| Ayala Pharmaceuticals | 13.00K |
BioStem Technologies News
- 7 days ago - BioStem Technologies, Inc. (BSEM) M&A Call Transcript - Seeking Alpha
- 8 days ago - BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies - PRNewsWire
- 8 days ago - BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business - GlobeNewsWire
- 6 weeks ago - BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes - GlobeNewsWire
- 7 weeks ago - BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference - GlobeNewsWire
- 2 months ago - BioStem Technologies, Inc. (BSEM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioStem Technologies Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - BioStem Technologies Announces Filing of Restated Financial Statements - GlobeNewsWire